Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

Intervention of aspirin on cardiovascular and cerebrovascular events in MHD patients

Aspirin Can Reduce Serum C Reactive Protein Level in Maintenance Hemodialysis Patients

The safety and efficiency of low-dose mineralocorticoid receptor antagonists in dialysis patients: a meta-analysis

Continuous aspirin treatment improves cardiovascular events and all-cause mortality in hemodialysis patients with peripheral artery disease

The Safety And Efficacy Of Low-Dose Mineralocorticoid Receptor Antagonists In Dialysis Patients A Meta-Analysis

Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

Hazardous Effect of Low-Dose Aspirin in Patients with Predialysis Advanced Chronic Kidney Disease Assessed by Machine Learning Method Feature Selection

The Effect of Aspirin on Preventing Vascular Access Dysfunction in Incident Hemodialysis Patients: A Prospective Cohort Study in Korean Clinical Research Centers for End-Stage Renal Disease (CRC for ESRD)

Low-Dose Aspirin for Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease

Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis

Impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease patients complicated with end-stage renal disease

China Collaborative Study on Dialysis: a Multi-Centers Cohort Study on Cardiovascular Diseases in Patients on Maintenance Dialysis

Effect of parathyroid hormone on myocardial damage,cardiac structure and function in maintenance hemodialysis patients

Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease

Preliminary application of ascorbate-rich dialysate on ameliorating oxidative stress in maintenance hemodialysis patients

Dialysis Methods May Affect Carotid Intima–Media Thickness in Chinese End-Stage Renal Disease Patients

MO201: Effects of Aspirin in Primary Prevention of Cardiovascular (CV) Disease in People with Chronic Kidney Disease (CKD): Results of the TIPS3 Trial

Primary Clinical Experience in High Risk Uremic Patients Converted from Conventional to Short Daily Hemodialysis

Effect and safety of aspirin for primary prevention of cardiovascular diseases:a systematic review and meta analysis